Non-Invasive Embryo Genetic Testing in Nungambakkam: Is niPGT Ready for IVF Decisions?

DNA in culture medium may come from different sources and may be present in limited or uneven amounts. Contamination, amplification artefacts and biological discordance can affect classification. In January 2026, Indian fertility experts from professional groups cautioned against using niPGT for routine embryo selection because evidence did not adequately establish accuracy or clinical benefit. That warning should not be confused with a ban on scientific research; it is a reason to protect clinical decisions.

niPGT is not interchangeable with established PGT-A, PGT-M or PGT-SR approaches, which themselves require careful indication-specific counselling and have limitations. A false abnormal result could lead to an embryo being wrongly deprioritised; a false reassuring result might provide inappropriate confidence. “No biopsy” does not mean “no risk of incorrect information”. Embryos should not be discarded on an unvalidated test result.

A useful review is selective, not a demand to repeat every fertility test. Bring the following material to the clinician who is actually responsible for the plan:

1. Written test name, specimen source, laboratory identity and validation materials.

2. Clinical reason genetic testing is being considered and family/genetic history.

3. Consent showing exactly how results would influence embryo selection or disposal.

4. Embryology report and any genetic counselling or prior PGT results.

These documents help the team check whether a result was obtained at the right time, with the right method, for the right question. If another person or laboratory provided a report, record their advice without assuming that the two teams have spoken directly. Why this matters for a real treatment decision is simple: a test, symptom or add-on can change what happens next only if the result is interpreted in context. Ask which finding would actually alter the treatment plan and which apparently abnormal detail is merely descriptive. Where the answer is uncertain, a safe pause for clarification is preferable to improvising a dose, test or procedure.

Ask whether the proposed test is research or routine clinical care, the actual sample and validation method, what independent accuracy data exist and whether the result would determine embryo transfer or disposal. Request genetic counselling when a known inherited disorder is the question. Discuss the evidence and limitations of conventional testing pathways before consenting to an experimental alternative.

| Possible path | What to confirm before choosing it |

|---|---|

| Do not use niPGT for routine selection | Follow current expert cautions while clinical utility remains unproven. |

| Consider indication-specific genetic counselling | Clarify whether PGT-M, PGT-SR or other testing is appropriate. |

| Discuss research participation separately | Demand ethics approval, consent and protection from unsupported embryo decisions. |

This is a discussion framework, not an algorithm or a prescription. A clinician may recommend a different sequence because of age, symptoms, medical history or the timing of a treatment cycle. Keep a dated, written record of the agreed plan.

A Nungambakkam couple is offered an inexpensive “biopsy-free genetic certificate” for every embryo. Instead of accepting it as a definitive screening guarantee, they ask for the laboratory’s validation data and the professional-society position, and request a consultation about whether any PGT is indicated for their specific reproductive or genetic history.

The point of this example is not to predict an outcome; it shows which missing detail would make the consultation more useful. In Nungambakkam, Chennai, a realistic coordination plan begins with a chronological list: period or treatment dates, prescriptions and exact dose times, laboratory reports with units and collection times, imaging reports and procedure summaries. Share the original files, not cropped screenshots. If different facilities are involved, ask which clinician owns the final decision and what changes require a physical appointment.

The practical goal is not to move laboratory procedures into a living room. A doctor-led plan can identify which conversations, record reviews, selected blood collections, medication or injection support, routine follow-up and care coordination may be suitable at or near home, where appropriate and actually available. Ultrasound when clinically required, egg retrieval, embryology work and embryo transfer remain facility-based. HomeIVF should confirm the exact services, location, eligibility and escalation process before a patient relies on this arrangement.

When discussing non-invasive preimplantation genetic testing (niPGT), start with an appropriate doctor-led consultation and a decision on the next required clinical assessment. If selected home blood collection, medication or injection support, or coordinated follow-up would help, ask HomeIVF to confirm eligibility and actual local availability first. No local clinic, partner, visiting doctor, pickup route, or service promise is implied.

Before accepting a recommendation, ask the clinician to describe a comparison: proceeding with standard care, gathering one more targeted piece of evidence, or choosing a different pathway if the clinical indication is clear. Request the expected benefit and limitations in ordinary language. A new charge, laboratory technique or visit should have a stated reason and should never be presented as a guaranteed route to pregnancy.

In this case, ask explicitly: whether this is research or validated routine care; what contamination and misclassification safeguards exist; if any embryo would be discarded based on the result. These questions make the visit actionable and can expose unnecessary repeat tests, confusion about ownership of a time-sensitive result or a promised benefit unsupported by evidence.

Embryology, embryo culture and any genetic testing are specialised laboratory activities subject to appropriate consent and governance. Do not use an unvalidated niPGT classification to discard, rank or transfer embryos without a qualified clinician and genetic professional reviewing its limitations. Protect confidentiality and identification documentation for all genetic samples.

Do not change hormone doses, discontinue prescribed medicines, attempt a procedure at home or interpret an isolated result as a treatment order. Severe pain, substantial bleeding, fainting, breathing difficulty, high fever or other sudden serious symptoms require prompt medical assessment. Your own fertility team should define additional condition-specific red flags and an emergency contact route.

A less invasive sample is not automatically a more reliable diagnostic test. Clinical embryo selection should rest on evidence, validated methods and informed consent, not on the promise of “genetic certainty without touching the embryo”.

The best next step is the one tied to your own test results and history, not the one that sounds most advanced. Seek medical advice from your treating doctor before changing care. The local service details and any additional clinical claims named in the verification section below must be checked before this page goes live.